stock.name

Mckesson Corporation

MCK

Market Cap$68.78B
Close$

Compare Mckesson

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Mckesson CorporationMckesson Corporation22.90.46%-146%0.2-2.9
marketMarket Avg59.71.27%30%-0.9
IndustrialsIndustrials Avg24.10.97%21%30.6

Earnings Call Q3 2024

February 7, 2024 - AI Summary

McKesson reported solid financial performance in the third quarter of fiscal 2024, with total revenues of $80.9 billion and adjusted earnings per diluted share of $7.74, both growing by double-digits compared to the prior year.
The company raised and narrowed its guidance range for fiscal 2024 adjusted earnings per diluted share from $26.80-$27.40 to an updated range of $27.25-$27.65.
McKesson's U.S. pharmaceutical segment showed strong momentum, with adjusted operating profit growing 6% and volume increases across customer channels, including specialty pharmaceuticals and GLP-1 medications.

Exclusive for Stockcircle Pro members

Sign upSign Up
$525.00

Target Price by Analysts

1.2% upsideMckesson Target Price DetailsTarget Price
$746.23

Current Fair Value

43.8% upside

Undervalued by 43.8% based on the discounted cash flow analysis.

Share Statistics

Market cap$68.78 Billion
Enterprise Value$72.68 Billion
Dividend Yield$2.3971 (0.46%)
Earnings per Share$22.11
Beta-0.0
Outstanding Shares131,408,286
Avg 30 Day Volume549,033

Return

Return on Equity-
Return on Assets-
Return on Invested Capital-

Valuation & Multiples

P/E Ratio22.94
PEG-50.52
Price to Sales0.23
Price to Book Ratio-32.43
Enterprise Value to Revenue0.24
Enterprise Value to EBIT18.72
Enterprise Value to Net Income24
Total Debt to Enterprise0.08
Debt to Equity-2.87

Revenue Sources

No data

ESG Score

No data

About Mckesson Corporation

80,000 employees
CEO: Brian Tyler

McKesson Corporation is a global leader in healthcare supply chain management solutions, retail pharmacy, community oncology and specialty care, and healthcare information solutions. McKesson partners with pharmaceutical manufacturers, p...